Clinical Trial Detail

NCT ID NCT01761266
Title A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eisai Limited
Indications

hepatocellular carcinoma

Therapies

Lenvatinib

Sorafenib

Age Groups: adult

No variant requirements are available.